ARTICLE | Clinical News
IC485: Started Phase I trial
November 12, 2001 8:00 AM UTC
Icos Corp. (ICOS), Bothell, Wash. Product: IC485 Business: Autoimmune/Inflammation Therapeutic category: Immune modulation Target: PDE4 Description: Small molecule oral PDE4 inhibitor Indication: T...